According to a regulatory filing, the inspection was conducted from 1 September to 5 September 2025. On conclusion, the USFDA issued a Form-483 with seven observations.
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC.
The company’s consolidated net profit rose 1.8% to Rs 1,418.10 crore on an 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25.
Shares of Dr Reddys Laboratories shed 0.04% to Rs 1,268 on the BSE.